Healthcare provider profile · identity verified

Nicole Ilonzo

Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · BROOKLYN, NY · NPI 1528486503

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Nicole Ilonzo received $29,783.48 in general payments during 2025 across 202 reported records.

Medtronic, Inc. accounted for 67.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 36 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$29,783.48

202 reported records · 11 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Medtronic, Inc. Medtronic, Inc.
exact · evidence 2025-07-22
$20,180.5667.8%932025
Bard Peripheral Vascular, Inc. Unresolved — no canonical attribution shown $3,947.1213.2%22025
Stryker Corporation Unresolved — no canonical attribution shown $2,857.489.6%542025
Penumbra, Inc. Unresolved — no canonical attribution shown $918.983.1%32025
Abbott Laboratories Unresolved — no canonical attribution shown $720.452.4%172025
Cagent Vascular INC Unresolved — no canonical attribution shown $551.191.9%152025
Tactile Systems Technology Inc Unresolved — no canonical attribution shown $249.120.8%102025
Inari Medical, Inc. Unresolved — no canonical attribution shown $212.730.7%32025
Shockwave Medical, Inc Unresolved — no canonical attribution shown $103.150.3%32025
Baxter Healthcare Unresolved — no canonical attribution shown $26.140.1%12025
VERTEX PHARMACEUTICALS INCORPORATED Unresolved — no canonical attribution shown $16.560.1%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Consulting Fee$8,943.753
Food and Beverage$8,626.20175
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$8,255.003
Travel and Lodging$3,958.5321

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
HAWKONE
Normalized: hawkone
Device Medtronic, Inc. $7,664.47 21 2025
Source payment records
TURBOHAWK
Normalized: turbohawk
Device Medtronic, Inc. $2,556.09 20 2025
Source payment records
CT THROMBECTOMY SYSTEM KIT
Normalized: ct thrombectomy system kit
Device Inari Medical, Inc., Stryker Corporation $939.87 17 2025
Source payment records
FLOWTRIEVER CATHETER, S
Normalized: flowtriever catheter s
Device Inari Medical, Inc., Stryker Corporation $939.87 17 2025
Source payment records
EVERCROSS
Normalized: evercross
Device Medtronic, Inc. $812.50 1 2025
Source payment records
ARTIX MT
Normalized: artix mt
Device Stryker Corporation $809.51 14 2025
Source payment records
Indigo System
Normalized: indigo system
Device Penumbra, Inc. $754.98 2 2025
Source payment records
LIMFLOW SYSTEM
Normalized: limflow system
Device Stryker Corporation $644.73 9 2025
Source payment records
Serrantor
Normalized: serrantor
Device Cagent Vascular INC $551.19 15 2025
Source payment records
ENDURANT IIS
Normalized: endurant iis
Device Medtronic, Inc. $427.52 7 2025
Source payment records
FLOWTRIEVER
Normalized: flowtriever
Device Stryker Corporation $414.60 12 2025
Source payment records
CONCERTOTM
Normalized: concertotm
Device Medtronic, Inc. $272.89 8 2025
Source payment records
Flexitouch Plus
Normalized: flexitouch plus
Device Tactile Systems Technology Inc $249.12 10 2025
Source payment records
Nimbl
Normalized: nimbl
Device Tactile Systems Technology Inc $249.12 10 2025
Source payment records
DIAMONDBACK PERIPHERAL
Normalized: diamondback peripheral
Device Abbott Laboratories $245.22 4 2025
Source payment records
ESPRIT
Normalized: esprit
Device Abbott Laboratories $243.77 7 2025
Source payment records
ABRE
Normalized: abre
Device Medtronic, Inc. $241.56 10 2025
Source payment records
CLOTTRIEVER BOLD CATHETER
Normalized: clottriever bold catheter
Device Stryker Corporation $240.02 4 2025
Source payment records
SILVERHAWK
Normalized: silverhawk
Device Medtronic, Inc. $199.92 2 2025
Source payment records
EMBOSHIELD NAV6
Normalized: emboshield nav6
Device Abbott Laboratories $186.13 4 2025
Source payment records
Penumbra System
Normalized: penumbra system
Device Penumbra, Inc. $164.00 1 2025
Source payment records
IN.PACT AV
Normalized: in pact av
Device Medtronic, Inc. $157.18 5 2025
Source payment records
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter
Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter
Device Shockwave Medical, Inc $103.15 3 2025
Source payment records
MVP
Normalized: mvp
Device Medtronic, Inc. $83.45 2 2025
Source payment records
CHOCOLATE PTA BALLOON CATHETER
Normalized: chocolate pta balloon catheter
Device Medtronic, Inc. $48.28 2 2025
Source payment records
PERCLOSE PROSTYLE
Normalized: perclose prostyle
Device Abbott Laboratories $45.33 2 2025
Source payment records
IN.PACT ADMIRAL
Normalized: in pact admiral
Device Medtronic, Inc. $43.08 2 2025
Source payment records
Pristine
Normalized: pristine
Device Bard Peripheral Vascular, Inc. $40.87 1 2025
Source payment records
PROTEGE RX
Normalized: protege rx
Device Medtronic, Inc. $40.43 1 2025
Source payment records
VALIANT CAPTIVIA
Normalized: valiant captivia
Device Medtronic, Inc. $29.83 1 2025
Source payment records
PERCLOT
Normalized: perclot
Device Baxter Healthcare $26.14 1 2025
Source payment records
NANOCROSS ELITE
Normalized: nanocross elite
Device Medtronic, Inc. $24.49 1 2025
Source payment records
INTHRILL THROMBECTOMY CATHETER
Normalized: inthrill thrombectomy catheter
Device Stryker Corporation $21.48 1 2025
Source payment records
SPIDERFX
Normalized: spiderfx
Device Medtronic, Inc. $20.65 1 2025
Source payment records
MO.MA ULTRA
Normalized: mo ma ultra
Device Medtronic, Inc. $19.78 1 2025
Source payment records
JOURNAVX
Normalized: journavx
Drug VERTEX PHARMACEUTICALS INCORPORATED $16.56 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
EliquisApixaban4014
Triamcinolone AcetonideTriamcinolone Acetonide24suppressed
Tramadol HclTramadol Hcl2216
GabapentinGabapentin19suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1313

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $29,783.48 · 202 records Medtronic, Inc. ABRE, ARTIX MT, CHOCOLATE PTA BALLOON CATHETER, CLOTTRIEVER BOLD CATHETER, CONCERTOTM, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, EMBOSHIELD NAV6, ENDURANT IIS, ESPRIT, EVERCROSS, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Flexitouch Plus, HAWKONE, IN.PACT ADMIRAL, IN.PACT AV, INTHRILL THROMBECTOMY CATHETER, Indigo System, JOURNAVX, LIMFLOW SYSTEM, MO.MA ULTRA, MVP, NANOCROSS ELITE, Nimbl, PERCLOSE PROSTYLE, PERCLOT, PROTEGE RX, Penumbra System, Pristine, SILVERHAWK, SPIDERFX, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURBOHAWK, VALIANT CAPTIVIA
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error